GLAXF GSK plc
Price Chart
Executive Summary
GSK announced positive phase 1 data for its investigational B7-H4-targeted antibody-drug conjugate mocertatug rezetecan (Mo-Rez), showing confirmed objective response rates of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer. The safety profile was manageable, supporting the initiation of five pivotal phase III trials in 2026.
Actionable Insight
Investors should monitor the initiation and enrollment of the five pivotal phase III trials in 2026, as well as safety and efficacy updates. The high response rates in difficult-to-treat populations suggest Mo-Rez could become a key asset in GSK's oncology portfolio, potentially commanding premium pricing and fast-track regulatory pathways.
Key Facts
- Mocertatug rezetecan achieved a 62% confirmed objective response rate (cORR) in platinum-resistant ovarian cancer (PROC) at 5.8 mg/kg (n=21/34; 95% CI: 44, 78)
- Achieved a 67% cORR in recurrent or advanced endometrial cancer (EC) at 4.8 mg/kg (n=8/12; 95% CI: 35, 90)
- Treatment discontinuation due to treatment-related adverse events was low (0% in PROC, 4% in EC)
- Grade ≥3 treatment-related adverse events occurred in 64% (PROC) and 54% (EC), primarily hematologic; interstitial lung disease was low (3%)
- Five pivotal phase III trials planned in 2026: BEHOLD-Ovarian01 (PROC), BEHOLD-Endometrial01 (2L EC), BEHOLD-Ovarian02 (platinum-sensitive), BEHOLD-Ovarian03 (first-line maintenance), and BEHOLD-Endometrial02 (mismatch-repair-proficient EC)
- Mo-Rez is a B7-H4-targeted ADC with a drug-to-antibody ratio of 6, licensed globally from Hansoh Pharma (excluding China, Hong Kong, Macau, Taiwan)
Financial Impact
Potential multibillion-dollar revenue opportunity; ovarian and endometrial cancers represent significant unmet needs with limited current therapies
Risk Factors
- Phase III trials may not replicate phase 1 efficacy results
- Safety profile could worsen in larger, more diverse populations
- Competition from other ADCs and immunotherapies in development for gynecologic cancers
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003422 |
| Document: 0001654954-26-003422-index-headers.html | 0001654954-26-003422 |
| Document: 0001654954-26-003422-index.html | 0001654954-26-003422 |
| Document: 0001654954-26-003422.txt | 0001654954-26-003422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
6-K
| $23.54 awaiting T+5 | awaiting T+5 | — | $26.63 (+13.13%) |
|
Jun 9, 2026
5d ago
|
6-K
| $24.66 awaiting T+5 | awaiting T+5 | — | $26.63 (+7.99%) |
|
Jun 9, 2026
5d ago
|
6-K
| $24.66 awaiting T+5 | awaiting T+5 | — | $26.63 (+7.99%) |
|
Jun 1, 2026
13d ago
|
6-K
| $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.63 (+9.81%) |
|
Jun 1, 2026
13d ago
|
6-K
| $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.63 (+9.81%) |
|
May 28, 2026
17d ago
|
6-K
| $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.63 (+8.34%) |
|
May 27, 2026
18d ago
|
6-K
| $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.63 (+4.15%) |
|
May 26, 2026
19d ago
|
6-K
| $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.63 (+4.43%) |
|
May 26, 2026
19d ago
|
6-K
| $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.63 (+4.43%) |
|
May 22, 2026
23d ago
|
6-K
| $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.63 (+2.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access